drugset
drugset / Trial / NCT02206867

Pharmacokinetics and Safety Study of LBAL in Healthy Subjects

NCT02206867 ↗

Phase 1 Completed 116 enrolled LG Life Sciences
RandomizedParallel-groupDouble-blindTreatment

Summary

To compare PK, safety and tolerability of LBAL developed by LG Life Sciences Ltd. With those of Humira®.

Timeline

Start
2014-08
Primary completion
2015-02
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Adalimumab Monoclonal antibody 40 mg Subcutaneous

Indications

No indication recorded.